Search Patents
  • surface protein SA1789 and protective vaccine based thereon
    Patent number: 8747858
    Abstract: The novel protein SA1789 from Staphylococcus aureus is provided as well as nucleic acid and nucleic acid sequence homologues encoding this protein. Also provided is a composition, particularly a S. aureus vaccine, comprising SA1789 protein or a fragment or derivative thereof capable of generating an immune response that leads to the killing and clearance of S. aureus.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: June 10, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tessie B. McNeely, Hongxia Fan, Mark Andrew Miller
  • Human sphingosine-1-phosphate phosphatase and inhibition methods
    Patent number: 7374889
    Abstract: The present invention provides polynucleotides and polypeptides of a human sphingosine-1-phosphate phosphatase, referred to herein as hSPP1. The polynucleotides and polypeptides are used to further provide expression vectors, host cells comprising the vectors, probes and primers, antibodies against the hSPP1 protein and polypeptides thereof, assays for the presence or expression of hSPP1 and assays for the identification of compounds that interact with hSPP1.
    Type: Grant
    Filed: February 6, 2002
    Date of Patent: May 20, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Suzanne M. Mandala, Rosemary A. Thornton
  • MurC gene and enzyme of
    Patent number: 7022829
    Abstract: This invention provides isolated polynucleotides that encode the MurC protein of Pseudomonas aeruginosa. Purified and isolated MurC recombinant proteins are also provided. Nucleic acid sequences which encode functionally active MurC proteins are described. Assays for the identification of modulators of the of expression of murC and inhibitors of the activity of MurC, are also provided.
    Type: Grant
    Filed: September 11, 2000
    Date of Patent: April 4, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Mohamend El-Sherbeini, Barbara Azzolina
  • G-CSF POLYPEPTIDES AND USES THEREOF
    Publication number: 20090275517
    Abstract: The present invention relates to G-CSF polypeptides and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides, as well as methods and tools for detecting or dosing these polypeptides in any sample.
    Type: Application
    Filed: June 26, 2009
    Publication date: November 5, 2009
    Applicant: MERCK SERONO S.A.
    Inventors: CATHERINE GONTHIER, PHILIPPE MILLASSEAU
  • Method of determination of receptor binding saturation effected by monoclonal antibodies
    Patent number: 8445219
    Abstract: The invention relates to the determination of the degree of membrane receptor binding by specific monoclonal antibodies. This method is notably beneficial for monoclonal antibodies that are used in targeted therapies in order to define a target effective dose (TED). Especially the invention relates to the determination of the saturation degree of receptor binding effected by an anti-EGFR antibody of interest.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: May 21, 2013
    Assignee: Merck Patent GmbH
    Inventors: Karl-August Reiffen, Oliver Rosen
  • Purified prostaglandin receptor FP
    Patent number: 5840847
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: November 24, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Mark Abramovitz, Richard Grygorczyk, Kathleen Metters, Truyen Nguyen, Thomas H. Rushmore, Deborah Slipetz
  • ACTIVE VARIANTS OF THE IL-18 BINDING PROTEIN AND MEDICAL USES THEREOF
    Publication number: 20110189131
    Abstract: The invention relates to active fragments of the IL-18 binding protein, to pharmaceutical compositions comprising such active fragments, and to medical uses thereof.
    Type: Application
    Filed: March 29, 2011
    Publication date: August 4, 2011
    Applicant: MERCK SERONO SA
    Inventors: VALTER ALTAROCCA, Anna R. Pezzotti
  • Therapeutic utility of plasminogen activator inhibitor-1 to control bleeding
    Patent number: 5254536
    Abstract: Pharmaceutical compositions for controlling, by topical administration, localized bleeding in a patient, the composition comprising active PAI-1 protein in an amount effective to control the localized bleeding when topically administered, and a vehicle suitable for the topical administration, as well as methods and kits employing the same, are disclosed.
    Type: Grant
    Filed: January 10, 1992
    Date of Patent: October 19, 1993
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: Adrienne L. Racanelli, Thomas M. Reilly
  • Human Prostaglandin receptor IP
    Patent number: 5728808
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: August 29, 1995
    Date of Patent: March 17, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Mark Abramovitz, Yves Bole, Richard Grygorczyk, Kathleen Metters, Thomas H. Rushmore, Deborah M. Slipetz
  • Human receptor tyrosine kinase, KDR
    Patent number: 6841367
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: January 11, 2005
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Kenneth A. Thomas, Xianzhi Mao, Andrew Tebben
  • Recombinant tumor specific antibody and use thereof
    Patent number: 7459538
    Abstract: The invention provides a family of antibodies that specifically bind the human epithelial cell adhesion molecule. The antibodies comprise modified variable regions, more specially, modified framework regions, which reduce their immunogenicity when administered to a human. The antibodies, when coupled to the appropriate moiety, may be used in the diagnosis, prognosis and treatment of cancer.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: December 2, 2008
    Assignee: Merck Patent GmbH
    Inventors: Stephen D. Gillies, Kin-Ming Lo, Susan Xiuqi Qian
  • HCV RNA-dependent RNA polymerase
    Patent number: 7329732
    Abstract: The present invention features NS5B polypeptides from different clinically important HCV genotypes. The polypeptides can be used individually, or as part of a panel of RNA-dependent RNA polymerases, to evaluate the effectiveness of a compound to inhibit NS5B activity.
    Type: Grant
    Filed: January 6, 2005
    Date of Patent: February 12, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Donald J. Graham, Amy L. Simcoe, Steven W. Ludmerer, Osvaldo A. Flores, Robert L. LaFemina
  • Anti-Cancer Antibodies With Reduced Complement Fixation
    Publication number: 20090148441
    Abstract: The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.
    Type: Application
    Filed: September 12, 2008
    Publication date: June 11, 2009
    Applicant: Merck Patent GmbH
    Inventor: Stephen D. Gillies
  • Human receptor tyrosine kinase, KDR
    Patent number: 6204011
    Abstract: An isolated nucleic acid molecule encoding a novel human receptor type tyrosine kinase gene, KDR, is disclosed. The isolation of this KDR cDNA sequence results in disclosure of purified forms of human KDR protein, recombinant vectors and recombinant hosts which express human KDR.
    Type: Grant
    Filed: June 17, 1998
    Date of Patent: March 20, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Richard L. Kendall, Xianzhi Mao, Kenneth A. Thomas, Andrew Tebben
  • Human papilloma virus vaccine with disassembled and reassembled virus-like particles
    Patent number: 6245568
    Abstract: Human Papillomavirus vaccine formulations which contain virus-like particles (VLPs) can be made more stable and have an enhanced shelf-life, by treating the VLPs to a disassembly and reassembly process. Also provided are formulation buffers to long term stable storage of VLPs.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: June 12, 2001
    Assignee: Merck & Co., Inc.
    Inventors: David B. Volkin, Henryk Mach, Li Shi
  • Using amines or amino acids as mobile phase modifiers in chromatography
    Patent number: 7241866
    Abstract: This invention relates to the use of amine, amino acid and amino acid ester mobile modifiers in normal phase chromatography to improve the resolution and or productivity of peptide and lipopeptide purification. This chromatographic method can be sued for either analytical or preparative scale purification.
    Type: Grant
    Filed: October 24, 2003
    Date of Patent: July 10, 2007
    Assignee: Merck & Co., Inc.
    Inventors: Kent E. Goklen, Joseph Nti-Gyabaah, Firoz D. Antia, Mary Ellen Dahlgren
  • Galanin receptor GALR3 and nucleotides encoding same
    Publication number: 20030023074
    Abstract: A new galanin receptor, GALR3, is described. Also provided are nucleic acids encoding same and various assays to identify ligands particular to said receptor. Ligands so identified are useful for the treatment of obesity, treatment of pain, and treatment of cognitive disorders.
    Type: Application
    Filed: August 6, 2002
    Publication date: January 30, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Andrew D. Howard, Margaret A. Cascieri, Roy G. Smith, Kathleen A. Sullivan, Carina Tan, Leonardus H.T. Van Der Ploeg, Kevin R. Lynch
  • Stabilized human papillomavirus formulations
    Patent number: 6358744
    Abstract: Human papillomavirus (HPV) antigen formulations are disclosed which prevent protein aggregation and show prolonged stability as aqueous solutions. These formulations comprise a salt (such as sodium chloride) and a non-ionic surfactant (Polysorbate 80 such as Tween 80®) in physiologically acceptable concentrations.
    Type: Grant
    Filed: July 24, 2000
    Date of Patent: March 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: David B. Volkin, Li Shi, Gautam Sanyal
  • DNA molecules encoding human nuclear receptor proteins
    Publication number: 20030119100
    Abstract: The present invention discloses the isolation and characterization of cDNA molecules encoding two human nuclear receptor proteins, designated nNR1, nNR2 and/or nNR2-1. Also within the scope of the disclosure are recombinant vectors, recombinant host cells, methods of screening for modulators of nNR1, nNR2 and/or nNR2-1 activity, and production of antibodies against nNR1, nNR2 and/or nNR2-1, or epitopes thereof.
    Type: Application
    Filed: January 23, 2002
    Publication date: June 26, 2003
    Applicant: Merck & Co., Inc.
    Inventor: Fang Chen
  • Protease inhibitor
    Patent number: 5397694
    Abstract: This invention relates to a novel protease-inhibitor,--which we called GELIN--and to pharmaceutical and cosmetic preparations thereof, containing this compound. GELIN is an inhibitor of human and porcine leucocyte elastase and chymotrypsin. GELIN has specific antibiotic properties. It also relates to the novel use of EGLIN, another chymotrypsin-inhibitor in cosmetic preparations.
    Type: Grant
    Filed: October 24, 1991
    Date of Patent: March 14, 1995
    Assignee: Merck Patent GmbH
    Inventors: Anthony Atkinson, Asgar Electricwala, Roy T. Sawyer, Nils von Sicard, Gerard Voerman